Altamira Therapeutics Ltd
NASDAQ:CYTO
Altamira Therapeutics Ltd
NASDAQ:CYTO
Price:
1.46 USD
-2.67%
Updated:
May 10, 2024
Altamira Therapeutics Ltd
Cash from Operating Activities
|
Altamira Therapeutics Ltd
Cash from Operating Activities Peer Comparison
Comparables:
NOVN
NLSP
ROG
S
SDZ
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Altamira Therapeutics Ltd
NASDAQ:CYTO
|
Cash from Operating Activities
-CHf11.5m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Novartis AG
SIX:NOVN
|
Cash from Operating Activities
$13.8B
|
CAGR 3-Years
1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
1%
|
|
|
NLS Pharmaceutics AG
NASDAQ:NLSP
|
Cash from Operating Activities
-$13.9m
|
CAGR 3-Years
-318%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
|
Roche Holding AG
SIX:ROG
|
Cash from Operating Activities
CHf16.1B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
0%
|
|
S
|
Sandoz Group AG
SIX:SDZ
|
Cash from Operating Activities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Altamira Therapeutics Ltd's Cash from Operating Activities?
Cash from Operating Activities
-11.5m
CHF
-11.5m
CHF
Based on the financial report for Dec 31, 2023, Altamira Therapeutics Ltd's Cash from Operating Activities amounts to -11.5m CHF.
What is Altamira Therapeutics Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
3%
3%
Over the last year, the Cash from Operating Activities growth was -33%. The average annual Cash from Operating Activities growth rates for Altamira Therapeutics Ltd have been -33% over the past three years , 3% over the past five years .
You don't have any saved screeners yet
